John D Koehn1, Paxton Bach2, Kanna Hayashi2, Paul Nguyen1, Thomas Kerr2, M-J Milloy2, Launette Rieb3, Evan Wood4. 1. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada. 2. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada; Department of Medicine, University of British Columbia, 10203-2775 Laurel Street, Vancouver, BC V5Z 1M3, Canada. 3. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada; Department of Family Practice, University of British Columbia, 3rd Floor, 5950 University Boulevard, Vancouver, BC V6T 1Z3, Canada. 4. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada; Department of Medicine, University of British Columbia, 10203-2775 Laurel Street, Vancouver, BC V5Z 1M3, Canada. Electronic address: uhri-ew@cfenet.ubc.ca.
Abstract
BACKGROUND: Despite barriers to its use in many settings, opioid agonist therapy with methadone has become the standard of care for treating opioid (e.g. heroin) use disorder. Since people with opioid use disorders have an increased incidence of incarceration, we undertook the present study to evaluate the association between incarceration and methadone maintenance therapy among a cohort of injection drug users in a Canadian setting. METHODS: A cohort of people who inject drugs was prospectively followed between May 1996 and May 2013 in Vancouver, Canada. We investigated the relationship between recent incarceration and methadone use using multivariate generalized estimating equation (GEE) logistic regression analysis. RESULTS: Overall, 2758 individuals were recruited during the study period and followed for a median of 64 (interquartile range: 23-106) months. After adjusting for various potential confounders in the multivariate GEE model, being incarcerated remained independently associated with a lower likelihood of having received methadone treatment (Adjusted Odds Ratio: 0.87, 95% confidence interval: 0.81-0.93). CONCLUSIONS: Our study demonstrates that incarceration was independently associated with a significantly lower likelihood of being on methadone. Given the role of methadone in reducing the harms of heroin use, including drug acquisitive crime and recidivism, these data suggest a need to scale-up methadone provision for incarcerated injection drug users.
BACKGROUND: Despite barriers to its use in many settings, opioid agonist therapy with methadone has become the standard of care for treating opioid (e.g. heroin) use disorder. Since people with opioid use disorders have an increased incidence of incarceration, we undertook the present study to evaluate the association between incarceration and methadone maintenance therapy among a cohort of injection drug users in a Canadian setting. METHODS: A cohort of people who inject drugs was prospectively followed between May 1996 and May 2013 in Vancouver, Canada. We investigated the relationship between recent incarceration and methadone use using multivariate generalized estimating equation (GEE) logistic regression analysis. RESULTS: Overall, 2758 individuals were recruited during the study period and followed for a median of 64 (interquartile range: 23-106) months. After adjusting for various potential confounders in the multivariate GEE model, being incarcerated remained independently associated with a lower likelihood of having received methadone treatment (Adjusted Odds Ratio: 0.87, 95% confidence interval: 0.81-0.93). CONCLUSIONS: Our study demonstrates that incarceration was independently associated with a significantly lower likelihood of being on methadone. Given the role of methadone in reducing the harms of heroin use, including drug acquisitive crime and recidivism, these data suggest a need to scale-up methadone provision for incarcerated injection drug users.
Authors: Anne Bukten; Svetlana Skurtveit; Michael Gossop; Helge Waal; Per Stangeland; Ingrid Havnes; Thomas Clausen Journal: Addiction Date: 2011-10-26 Impact factor: 6.526
Authors: Anne Bukten; Svetlana Skurtveit; Per Stangeland; Michael Gossop; Astrid B Willersrud; Helge Waal; Ingrid Havnes; Thomas Clausen Journal: J Subst Abuse Treat Date: 2011-08-11
Authors: Michelle McKenzie; Nickolas Zaller; Samuel L Dickman; Traci C Green; Amisha Parihk; Peter D Friedmann; Josiah D Rich Journal: Subst Abus Date: 2012 Impact factor: 3.716
Authors: Heather Schacht Reisinger; Robert P Schwartz; Shannon Gwin Mitchell; James A Peterson; Sharon M Kelly; Kevin E O'Grady; Erica A Marrari; Barry S Brown; Michael H Agar Journal: J Psychoactive Drugs Date: 2009-09
Authors: Ezequiel Blumenkrans; Jonah Hamilton; N A Mohd Salleh; Angela Kaida; Will Small; Rolando Barrios; M-J Milloy Journal: J Correct Health Care Date: 2022-06-27
Authors: Nicole M Luongo; Huiru Dong; Thomas H Kerr; M-J S Milloy; Kanna Hayashi; Lindsey A Richardson Journal: Addict Behav Date: 2016-08-31 Impact factor: 3.913
Authors: Ugochukwu Uzoeghelu; Laura M Bogart; Taylor Mahoney; Musie S Ghebremichael; Jelani Kerr; Bisola O Ojikutu Journal: J Racial Ethn Health Disparities Date: 2021-02-05
Authors: Jack Stone; Hannah Fraser; Aaron G Lim; Josephine G Walker; Zoe Ward; Louis MacGregor; Adam Trickey; Sam Abbott; Steffanie A Strathdee; Daniela Abramovitz; Lisa Maher; Jenny Iversen; Julie Bruneau; Geng Zang; Richard S Garfein; Yung-Fen Yen; Tasnim Azim; Shruti H Mehta; Michael-John Milloy; Margaret E Hellard; Rachel Sacks-Davis; Paul M Dietze; Campbell Aitken; Malvina Aladashvili; Tengiz Tsertsvadze; Viktor Mravčík; Michel Alary; Elise Roy; Pavlo Smyrnov; Yana Sazonova; April M Young; Jennifer R Havens; Vivian D Hope; Monica Desai; Ellen Heinsbroek; Sharon J Hutchinson; Norah E Palmateer; Andrew McAuley; Lucy Platt; Natasha K Martin; Frederick L Altice; Matthew Hickman; Peter Vickerman Journal: Lancet Infect Dis Date: 2018-10-29 Impact factor: 71.421